WO2002015919A3 - Saratin for inhibiting platelet adhesion to collagen - Google Patents

Saratin for inhibiting platelet adhesion to collagen Download PDF

Info

Publication number
WO2002015919A3
WO2002015919A3 PCT/EP2001/009746 EP0109746W WO0215919A3 WO 2002015919 A3 WO2002015919 A3 WO 2002015919A3 EP 0109746 W EP0109746 W EP 0109746W WO 0215919 A3 WO0215919 A3 WO 0215919A3
Authority
WO
WIPO (PCT)
Prior art keywords
saratin
platelet adhesion
collagen
inhibiting platelet
polypeptide
Prior art date
Application number
PCT/EP2001/009746
Other languages
French (fr)
Other versions
WO2002015919A2 (en
Inventor
Christopher Barnes
Matthias Frech
Uwe Hofmann
Johannes Gleitz
Wolfgang Strittmatter
Original Assignee
Merck Patent Gmbh
Christopher Barnes
Matthias Frech
Uwe Hofmann
Johannes Gleitz
Wolfgang Strittmatter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PT01976139T priority Critical patent/PT1311284E/en
Priority to BR0113478-7A priority patent/BR0113478A/en
Application filed by Merck Patent Gmbh, Christopher Barnes, Matthias Frech, Uwe Hofmann, Johannes Gleitz, Wolfgang Strittmatter filed Critical Merck Patent Gmbh
Priority to UA2003032476A priority patent/UA77402C2/en
Priority to DE60107962T priority patent/DE60107962T2/en
Priority to KR1020037002188A priority patent/KR100794277B1/en
Priority to EP01976139A priority patent/EP1311284B1/en
Priority to SI200130310T priority patent/SI1311284T1/xx
Priority to US10/362,476 priority patent/US6881722B2/en
Priority to JP2002520840A priority patent/JP4988131B2/en
Priority to AU2001295506A priority patent/AU2001295506B2/en
Priority to HU0303747A priority patent/HU229367B1/en
Priority to DK01976139T priority patent/DK1311284T3/en
Priority to AT01976139T priority patent/ATE285246T1/en
Priority to MXPA03001604A priority patent/MXPA03001604A/en
Priority to AU9550601A priority patent/AU9550601A/en
Priority to SK313-2003A priority patent/SK287829B6/en
Priority to CA2419385A priority patent/CA2419385C/en
Publication of WO2002015919A2 publication Critical patent/WO2002015919A2/en
Publication of WO2002015919A3 publication Critical patent/WO2002015919A3/en
Priority to NO20030841A priority patent/NO331326B1/en
Priority to HK04102595A priority patent/HK1059736A1/en
Priority to US11/016,854 priority patent/US7459438B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

Use of the polypeptide Saratin for the manufacture of a medicament having the capability to significantly decrease platelet adhesion and platelet accumulation after vascular injuries or endarterectomy. The invention furthermore relates to a novel medical use of Saratin as an inhibitor of thrombosis and intimal hyperplasia, wherein said polypeptide may be used locally as a topical agent or as a coating on, or otherwise incorporated or associated with medical devices.
PCT/EP2001/009746 2000-08-25 2001-08-23 Saratin for inhibiting platelet adhesion to collagen WO2002015919A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SK313-2003A SK287829B6 (en) 2000-08-25 2001-08-23 Saratin for inhibiting platelet adhesion to collagen
AU2001295506A AU2001295506B2 (en) 2000-08-25 2001-08-23 Saratin for inhibiting platelet adhesion to collagen
UA2003032476A UA77402C2 (en) 2000-08-25 2001-08-23 Use of saratin for inhibition platelet adhesion
DE60107962T DE60107962T2 (en) 2000-08-25 2001-08-23 SARATIN FOR INHIBITING PLATZADHESIS ON COLLAGEN
KR1020037002188A KR100794277B1 (en) 2000-08-25 2001-08-23 A new specific mechanism for inhibiting platelet adhesion to collagen
EP01976139A EP1311284B1 (en) 2000-08-25 2001-08-23 Saratin for inhibiting platelet adhesion to collagen
SI200130310T SI1311284T1 (en) 2000-08-25 2001-08-23
US10/362,476 US6881722B2 (en) 2000-08-25 2001-08-23 Saratin for inhibiting platelet adhesion to collagen
DK01976139T DK1311284T3 (en) 2000-08-25 2001-08-23 A new specific mechanism for inhibiting platelet adhesion to collagen
PT01976139T PT1311284E (en) 2000-08-25 2001-08-23 A NEW SPECIFIC MECHANISM TO INHIBIT THE ADHESION OF PLATELETS TO COLLAGEN
HU0303747A HU229367B1 (en) 2000-08-25 2001-08-23 Saratin for inhibiting platelet adhesion to collagen
JP2002520840A JP4988131B2 (en) 2000-08-25 2001-08-23 A novel specific mechanism for inhibiting platelet adhesion to collagen
AT01976139T ATE285246T1 (en) 2000-08-25 2001-08-23 SARATIN FOR INHIBITING PLATELE ADHESION ON COLLAGEN
MXPA03001604A MXPA03001604A (en) 2000-08-25 2001-08-23 A new specific mechanism for inhibiting platelet adhesion to collagen.
AU9550601A AU9550601A (en) 2000-08-25 2001-08-23 A new specific mechanism for inhibiting platelet adhesion to collagen
BR0113478-7A BR0113478A (en) 2000-08-25 2001-08-23 Specific mechanism for inhibition of platelet adhesion to collagen
CA2419385A CA2419385C (en) 2000-08-25 2001-08-23 Saratin for inhibiting platelet adhesion to collagen
NO20030841A NO331326B1 (en) 2000-08-25 2003-02-24 Use of saratin for the manufacture of a drug for inhibiting platelet adhesion to collagen
HK04102595A HK1059736A1 (en) 2000-08-25 2004-04-14 A new specific mechanism for inhibiting platelet adhesion to collagen
US11/016,854 US7459438B2 (en) 2000-08-25 2004-12-21 Specific mechanism for inhibiting platelet adhesion to collagen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00118542 2000-08-25
EP00118542.0 2000-08-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10362476 A-371-Of-International 2001-08-23
US11/016,854 Division US7459438B2 (en) 2000-08-25 2004-12-21 Specific mechanism for inhibiting platelet adhesion to collagen

Publications (2)

Publication Number Publication Date
WO2002015919A2 WO2002015919A2 (en) 2002-02-28
WO2002015919A3 true WO2002015919A3 (en) 2002-05-30

Family

ID=8169664

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009746 WO2002015919A2 (en) 2000-08-25 2001-08-23 Saratin for inhibiting platelet adhesion to collagen

Country Status (27)

Country Link
US (2) US6881722B2 (en)
EP (1) EP1311284B1 (en)
JP (1) JP4988131B2 (en)
KR (1) KR100794277B1 (en)
CN (1) CN1224421C (en)
AR (1) AR030492A1 (en)
AT (1) ATE285246T1 (en)
AU (2) AU2001295506B2 (en)
BR (1) BR0113478A (en)
CA (1) CA2419385C (en)
CZ (1) CZ302353B6 (en)
DE (1) DE60107962T2 (en)
DK (1) DK1311284T3 (en)
EC (1) ECSP034485A (en)
ES (1) ES2234896T3 (en)
HK (1) HK1059736A1 (en)
HU (1) HU229367B1 (en)
MX (1) MXPA03001604A (en)
MY (1) MY128992A (en)
NO (1) NO331326B1 (en)
PT (1) PT1311284E (en)
RU (1) RU2302880C2 (en)
SI (1) SI1311284T1 (en)
SK (1) SK287829B6 (en)
UA (1) UA77402C2 (en)
WO (1) WO2002015919A2 (en)
ZA (1) ZA200302296B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691839B2 (en) 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4805461B2 (en) * 1999-03-18 2011-11-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Protein for blocking platelet adhesion
EP2390270A1 (en) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
US20110034396A1 (en) * 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
US20080069774A1 (en) * 2005-11-17 2008-03-20 Lance Liotta Proteomic antisense molecular shield and targeting
CN117229423B (en) * 2023-11-10 2024-02-06 北京科技大学 Polypeptide nano material for binding collagen and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007005A1 (en) * 1990-10-10 1992-04-30 Merck Patent Gmbh Platelet adhesion inhibitor
US5246715A (en) * 1988-06-24 1993-09-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same
WO1995001375A1 (en) * 1993-07-01 1995-01-12 Merck Patent Gmbh Inhibitor of collagen-stimulated platelet aggregation
WO2000056885A1 (en) * 1999-03-18 2000-09-28 Merck Patent Gmbh Protein for blocking platelet adhesion

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947401A (en) * 1971-10-05 1976-03-30 Union Optics Corporation Hydrogels of unsaturated ester copolymers
US5705355A (en) 1984-03-27 1998-01-06 Transgene, S.A. Hirudin, pharmaceutical compositions comprising it and their use
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
CA2052486A1 (en) * 1990-10-09 1992-04-10 Thomas M. Connolly Protein for inhibiting collagen-stimulated platelet aggregation
US5179082A (en) * 1990-11-13 1993-01-12 Merck & Co., Inc. Method for blocking platelet adhesion to collagen
DE4136513A1 (en) 1991-11-06 1993-05-13 Basf Ag NEW THROMBIN INHIBITORIC PROTEIN FROM RUBBER BUGS
PT1118325E (en) * 1993-07-29 2006-05-31 Us Health USES OF PACLITAXEL AND ITS DERIVATIVES IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF RESTENOSE
US5532287A (en) * 1994-05-04 1996-07-02 Ciba-Geigy Corporation Radiation cured drug release controlling membrane
US6246715B1 (en) * 1998-06-26 2001-06-12 Samsung Electronics Co., Ltd. Data transmitter and receiver of a DS-CDMA communication system
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
AU6425699A (en) * 1998-10-16 2000-05-08 Cornell Research Foundation Inc. Methods of inhibiting platelet activation and recruitment
IT1304135B1 (en) * 1998-11-26 2001-03-07 Magneti Marelli Spa INJECTION AND IGNITION CONTROL METHOD IN A DIRECT INJECTION THERMAL ENGINE TO ACCELERATE THE HEATING OF THE
HUP0105284A3 (en) * 1999-02-19 2003-12-29 Zymogenetics Inc Seattle Inhibitors for use in hemostasis and immune function

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246715A (en) * 1988-06-24 1993-09-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same
WO1992007005A1 (en) * 1990-10-10 1992-04-30 Merck Patent Gmbh Platelet adhesion inhibitor
WO1995001375A1 (en) * 1993-07-01 1995-01-12 Merck Patent Gmbh Inhibitor of collagen-stimulated platelet aggregation
WO2000056885A1 (en) * 1999-03-18 2000-09-28 Merck Patent Gmbh Protein for blocking platelet adhesion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARNES C S ET AL: "Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen.", SEMINARS IN THROMBOSIS AND HEMOSTASIS, (2001 AUG) 27 (4) 337-48. REF: 54, XP001027785 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691839B2 (en) 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US8188034B2 (en) 2005-09-28 2012-05-29 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation

Also Published As

Publication number Publication date
CN1224421C (en) 2005-10-26
HU229367B1 (en) 2013-11-28
DE60107962D1 (en) 2005-01-27
DE60107962T2 (en) 2005-12-15
MY128992A (en) 2007-03-30
MXPA03001604A (en) 2003-06-04
NO20030841L (en) 2003-02-24
KR20030034141A (en) 2003-05-01
PT1311284E (en) 2005-05-31
EP1311284B1 (en) 2004-12-22
SK287829B6 (en) 2011-11-04
ATE285246T1 (en) 2005-01-15
CZ2003720A3 (en) 2003-06-18
US20030190342A1 (en) 2003-10-09
NO331326B1 (en) 2011-11-28
US20050143305A1 (en) 2005-06-30
CZ302353B6 (en) 2011-03-30
AU9550601A (en) 2002-03-04
CA2419385A1 (en) 2002-02-28
US7459438B2 (en) 2008-12-02
EP1311284A2 (en) 2003-05-21
DK1311284T3 (en) 2005-04-18
SK3132003A3 (en) 2003-08-05
HK1059736A1 (en) 2004-07-16
JP4988131B2 (en) 2012-08-01
WO2002015919A2 (en) 2002-02-28
CN1449291A (en) 2003-10-15
JP2004506690A (en) 2004-03-04
HUP0303747A3 (en) 2006-01-30
ES2234896T3 (en) 2005-07-01
ZA200302296B (en) 2004-06-30
US6881722B2 (en) 2005-04-19
ECSP034485A (en) 2003-03-31
KR100794277B1 (en) 2008-01-11
HUP0303747A2 (en) 2004-03-01
UA77402C2 (en) 2006-12-15
RU2302880C2 (en) 2007-07-20
BR0113478A (en) 2003-07-15
AR030492A1 (en) 2003-08-20
CA2419385C (en) 2011-05-10
AU2001295506B2 (en) 2007-02-15
SI1311284T1 (en) 2005-08-31
PL359246A1 (en) 2004-08-23
NO20030841D0 (en) 2003-02-24

Similar Documents

Publication Publication Date Title
IL162719A0 (en) Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin andderivatives thereof
WO2003045523A3 (en) Therapeutic coating for an intravascular implant
AU2002365875A1 (en) Stent designed for the delivery of therapeautic substance or other agents
AU6158001A (en) Drug/drug delivery systems for the prevention and treatment of vascular disease
AU2002225780A1 (en) Coating with anti-microbial agent for refrigerator shelving
ZA979822B (en) Methods for treating non-suturable, superficial wounds by use of cyanoacrylate ester compositions comprising an antimicrobial agent.
BR0010659B1 (en) Method for the manufacture of absorbent article having fastening feature with small self-adhesion.
WO2001085201A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
WO2003072154A8 (en) Composition and method for coating medical devices
WO2002015919A3 (en) Saratin for inhibiting platelet adhesion to collagen
AU2002330850A1 (en) Use of inhibitors of the abc drug transporter to increase the activity of anti-microbial agents
EP0870502A3 (en) Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
WO2002064160A3 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
WO1998053850A3 (en) Compositions and means for the treatment of burns and other cutaneous traumas
EP1806144A3 (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
WO2002022107A3 (en) Pharmaceutical composition having modified carrier
AU2001244461A1 (en) Venous line catheter and method of operating the same
HUP0001097A3 (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
WO2002022074A3 (en) Use of 2- and 4- quinolones for inhibiting intimal neo-proliferation
AU2001287560A1 (en) Agent for inhibiting adhesion of the pathogenic flora of the skin
AR027958A1 (en) COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES, INCLUDING PROPIONIL L-CARNITINE AND COENZYME Q10
MY140504A (en) Statin-mmp inhibitor combinations
AU2001281392A1 (en) Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
WO2005014021A3 (en) Use of zkw peptide for preparing an inhibitor drug against platelet aggregation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200300282

Country of ref document: VN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001976139

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020037002188

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001604

Country of ref document: MX

Ref document number: 2419385

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10362476

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001295506

Country of ref document: AU

Ref document number: 018146600

Country of ref document: CN

Ref document number: 2002520840

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PV2003-720

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 3132003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 331/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003/02296

Country of ref document: ZA

Ref document number: 200302296

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2003107919

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWP Wipo information: published in national office

Ref document number: 1020037002188

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001976139

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-720

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001976139

Country of ref document: EP